Objective: Mutations in the aggrecan gene (ACAN) have been identified in two autosomal dominant skeletal dysplasias, spondyloepiphyseal dysplasia, Kimberley type (SEDK), and osteochondritis dissecans, as well as in a severe recessive dysplasia, spondyloepimetaphyseal dysplasia, aggrecan type. Next-generation sequencing (NGS) has aided the identification of heterozygous ACAN mutations in individuals with short stature, minor skeletal defects and mild facial dysmorphisms, some of whom have advanced bone age (BA), poor pubertal spurt and early growth cessation as well as precocious osteoarthritis.
| INTRODUC TI ON
Results: A total of 16 ACAN variants were located throughout the gene, six pathogenic mutations and 10 variants of unknown significance (VUS). Interestingly, brachydactyly was observed in all probands. Probands from group 1 with a pathogenic mutation tended to be shorter, and 60% had an advanced BA compared to 0% in those with a VUS. A higher incidence of coxa valga was observed in individuals with a VUS (37% vs 0%). Nevertheless, other features were present at similar frequencies.
Conclusions: ACAN should be considered as a candidate gene in patients with short stature and minor skeletal defects, particularly those with brachydactyly, and in patients with spondyloepiphyseal dysplasia. It is also important to note that advanced BA and osteoarticular complications are not obligatory conditions for aggrecanopathies/aggrecan-associated dysplasias.
K E Y W O R D S
ACAN, aggrecan, brachydactyly, short stature, skeletal dysplasia F I G U R E 1 Structure of ACAN and the locations of the variants identified in the 16 probands. The G1 region encoded by exons 3-6, the IGD region by exon 7, the G2 region by exons 8-10, the GAG (KS-CS1-CS2) attachment region encoded by exons 11-12, while the G3 region encoded by exons [13] [14] [15] [16] [17] [18] [19] 
| PATIENTS AND ME THODS
All participants provided informed consent for the conducted studies, and the ethical approval was obtained from the Hospital La Paz Ethical Committee.
The 16 probands were referred for molecular study from Spanish and Portuguese endocrinology and genetic clinics. Ten formed part of a cohort of 100 children with short stature and mild skeletal defects in either the proband or one of their parents, in whom SHOX defects had been previously excluded using MLPA (P018G1, MRC Holland) and DNA sequencing. Endocrine disorders including GH-IGF1-related conditions were also excluded by biochemical analysis.
The remaining six probands were referred for routine skeletal dysplasia genetic diagnosis (n > 1000 patients). SHOX mutations were similarly excluded in four of these, not conducted in probands [15] [16] . BA and skeletal surveys were carried out. Blood samples were extracted from the proband and family members, when available.
All probands were analysed using a custom-designed skeletal dysplasia next-generation sequencing (NGS) panel, SKELETALSEQ.V3-6
(n = 315-368 genes) and sequenced on a MiSeq/NextSeq sequencer (Illumina, San Diego, CA, USA). Bioinformatic analyses were conducted as previously described. Gene and protein domain localization indicated. Conservation, in silico pathogenicity predictions and number of affected family members shown for each mutation. ACMG classification also indicated.
π Splicing tools in Alamut V2.10 predicted that it may affect splicing, but a minigene assay did not confirm these predictions. *Splicing tools predict the ablation of intron 1 canonical splice acceptor site, which was subsequently confirmed using a minigene assay.
TA B L E 1 (Continued) spurt and other associated medical conditions, similar to that previously published. 6 Advanced BA was defined as a BA greater than 1 year compared to the CA, while delayed BA was defined as BA less than 1 year relative to the CA. Brachydactyly was defined as short metacarpals and/or fingers. The clinical data, BA and skeletal surveys were then revised by three experts (LS-M, AO and MP).
Subsequently, the 16 probands were divided into two clinical groups:
those presenting with short stature and mild skeletal defects (group 1, probands 1-14) and two with SEDK (group 2, probands 15-16).
| RE SULTS

| Molecular genetics
A total of 16 heterozygous ACAN variants were identified ( Figure 1 , characteristics are shown in Table 2 . Anthropometric measurements were assessed in the 13 children of group 1. The median height SDS was below average (−2.9), sitting height-to-height ratio was in the normal range (0.54), and BMI was −0.31 SDS. Advanced BA was observed in three probands, while equal or delayed BA with respect to CA was determined in ten. Three probands had reached their final height, two of whom had had a poor pubertal spurt. Examples of growth patterns are shown in Figure S1 . Radiological features and hand photographs are shown in Figures S2 and S3 , respectively.
Brachydactyly (short fingers and/or short metacarpals) was observed in all probands in group 1. Seven probands (53%) showed a similar phenotype with frontal bossing, depressed nasal bridge and/ or mid-facial dysplasia ( Table 2) . Three of the patients (probands 2, 9 and 12) have recently initiated growth hormone therapy, but no response data are currently available. To determine whether the clinical characteristics were similar or different in individuals with a clearly pathogenic mutation compared to those with a VUS, we made a comparison of the clinical and radiological characteristics of these probands from group 1 ( Table 3 ).
| Group 2 (probands 15-16)-SEDK
Heterozygous ACAN mutations were identified in the two probands with moderate skeletal anomalies including platyspondyly, who were subsequently diagnosed as having SEDK (Table 1) . Proband 15 was found to have a mutation in the canonical splice acceptor site of intron 1 (c.-7-2A>C), which is predicted to result in the removal of exon 2, where the initiation codon is located. We demonstrated, using a minigene assay, that this mutation indeed ablated the intron 1 splice acceptor site, thus confirming the pathogenicity of this variant ( Figure S4 ). The second case, proband 16, has a missense variant (VUS) in ACAN (p.Thr533Ile). Clinical and radiological characteristics of both probands are shown in Table 4 and Figure   S2 , respectively.
| D ISCUSS I ON
A total of 16 heterozygous variants were detected throughout ACAN, 14 in individuals with short stature, mild skeletal defects and/ or facial dysmorphisms (group 1) and two with SEDK (group 2). No other mutation/variant was identified in the skeletal dysplasia patient in the 16 probands, which could explain their phenotype. As functional characterization is not currently feasible for confirming the pathogenicity of the ACAN VUS, we compared the clinical features in probands from group 1 with a pathogenic mutation (nonsense, frameshift, splicing, n = 5) and those with VUS (missense variants, n = 8) (Table 3) . Individuals with a pathogenic mutation were shorter (median −3.33 vs −2.7 SDS), and 60% had an advanced BA compared to 0% in those with a VUS. Advanced BA:CA was only observed in 3/5 individuals with a pathogenic mutation; thus, two individuals had a BA equal or delayed with respect to the CA. To date, a total of 58 probands and 106 family members (total = 164 heterozygous ACAN-positive individuals with short stature and mild skeletal defects) have been reported in this study and in the literature (Table 5) . [4] [5] [6] [7] [8] [9] [10] . Although advanced BA is a good indicator for the presence of mutations in ACAN, it cannot be the principal selection criteria. The other major difference was that a third of the individuals with a VUS had coxa valga, whereas no individual with a pathogenic mutation presented with this clinical feature. Nevertheless, other features such as skeletal defects, facial dysmorphisms and precocious arthropathy or discopathy were present at similar frequencies in both variant classification groups. An interesting observation and in contrast to previous data, brachydactyly was observed in all probands.
After analysing the individuals according to the variant classification, we conducted a study of the clinical features of the probands and affected family members from group 1 (n = 32; 14 children and 18 adults). No sex or ethnic differences were observed. Only 23% of the children had advanced BA, once again significantly lower than that previously described ( Table 5 ). The degree of short stature was also very variable. Another previously undescribed feature was the presence of mild hip abnormalities in five probands (38%). Parents of two of these probands suffer with osteoarthritis. Osteoarthritis and disc disease were uncommon in our cohort with only three parents having these medical complications (23%) ( Table 5) .
Clinical heterogeneity occurred in some families, as previously reported in a few cases. Ns, nonsense mutation; Fs, frameshift mutation; Spl, splice donor site variant; Mis, missense variant; NR, not reported. *Three families are included in the International Aggrecan Consortium (5 children, 9 adults).
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**the family reported in this study is included in the International Aggrecan Consortium (1 child, two adults).
***two families (two children, two adults) are included in the International Aggrecan Consortium.
Results shown here are related to the paediatric cohort.
reported a large cohort of probands and relatives (International Aggrecan Consortium). Clinical and molecular characteristics are related to the 20 families, not to individuals as with the other studies. In addition, data were compiled from both adults and children. We have attempted to separate these data when possible. §
Combined data from the current study and previous studies. The numbers documented for type of mutation, early-onset arthritis/OD and intervertebral disc disease data are given as the number of families, while the other characteristics are totals for the number of individuals (probands or adults). Once again, most of the data from the International Aggrecan Consortium (¥ ref [6] ) cannot be summarized as the data are presented for families rather than individuals. Patients included in three earlier studies (*, **, ***) have not been duplicated in these data.
that surprising as SHOX binds to SOX5 and SOX6 which along with SOX9 (SOX trio) activate an aggrecan enhancer, thus participating in common regulatory pathways in chondrogenesis. 15 The description of our cohort supports the undertaking of a de- cohorts, generation of animal models and functional analysis will be also required to determine the incidence of ACAN mutations and the pathogenic mechanism(s).
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